Vorasidenib
INDIGO
Servier · Phase 3 · Active, not recruiting · Enrollment 331
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Vorasidenib 40 mg daily | grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163) | 40 mg | ITT | placebo | PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysistime to next intervention hazard ratio: 0.26 HR, primary analysismedian time to next intervention, placebo: 17.8 months, primary analysismedian PFS, vorasidenib: 27.7 months, NEJM 2023median PFS, placebo: 11.1 months, NEJM 2023median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminaryobjective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary |